Peginterferon α-2a (40kD) [Pegasys®] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon®-A]In Patients with Chronic Hepatitis C

被引：0
作者：
Jens Rasenack
Stefan Zeuzem
S. Victor Feinman
E. Jenny Heathcote
Michael Manns
Eric M. Yoshida
Mark G. Swain
Edward Gane
Moises Diago
Dennis A. Revicki
Amy Lin
Neil Wintfeld
Jesse Green
机构：
[1] Klinikum der Albert-Ludwigs-Universität,Innere Medizin II
[2] Klinikum der J.W. Goethe-Universität,undefined
[3] Mount Sinai Hospital,undefined
[4] University Health Network - Toronto Western Hospital,undefined
[5] Kliniken Der Medizinischen Hochschule,undefined
[6] University of British Columbia,undefined
[7] University of Calgary,undefined
[8] Middlemore Hospital,undefined
[9] Hospital General De Valencia,undefined
[10] MEDTAP International Inc.,undefined
[11] F. Hoffmann-La Roche Inc.,undefined
来源：
PharmacoEconomics | 2003年 / 21卷
关键词：
Chronic Hepatitis; Sustained Virological Response; Physical Component Summary; Mental Component Summary; Fatigue Severity Scale;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Use of unmodified interferon α-2a in chronic hepatitis C is associated with impaired health-related quality of life during therapy. Treatment with peginterferon α-2a (40kD) provides an improved sustained response over unmodified interferon α-2a.
引用
收藏
页码：341 / 349
页数：8
相关论文
共 54 条
  • [1] Alter MJ(1999)Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 6 35-47
  • [2] Kruszon-Moran D(1999)The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 556-62
  • [3] Nainan OV(1994)Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile Clin Ther 16 334-43
  • [4] Davis GL(1994)Assessment of the health-related quality of life (HRQL) of patients with chronic hepatitis C (CHC) Gastroenterology 106 A393-5
  • [5] Balart LA(1999)Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group Hepatology 30 550-70
  • [6] Schiff ER(1999)Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group Hepatology 29 264-8S
  • [7] Ware J(1997)Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials Hepatology 26 83S-89
  • [8] Bungay K(1996)Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Hepatology 24 778-100S
  • [9] Bandek B(1997)Therapy of hepatitis C: interferon alfa-n1 trials Hepatology 26 96S-32
  • [10] Ware J(1998)Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1426-92
123456